Trials / Completed
CompletedNCT03805984
Safety, Tolerability and Immunogenicity of INO-4500 in Healthy Volunteers
Study to Evaluate the Safety, Tolerability and Immunogenicity of INO-4500 in Healthy Volunteers
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 60 (actual)
- Sponsor
- Inovio Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Accepted
Summary
This is a randomized and double-blinded within study group, placebo-controlled trial to evaluate the safety, tolerability and immunological profile of INO-4500 administered by intradermal (ID) injection followed by electroporation using the CELLECTRA® 2000 device in healthy adult volunteers.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | INO-4500 | INO-4500 will be administered ID on Day 0 and Week 4. |
| DRUG | Placebo | Placebo will be administered ID on Day 0 and Week 4. |
| DEVICE | CELLECTRA® 2000 | EP using the CELLECTRA® 2000 device will be administered following ID drug administration. |
Timeline
- Start date
- 2019-05-09
- Primary completion
- 2020-10-21
- Completion
- 2020-10-21
- First posted
- 2019-01-16
- Last updated
- 2020-11-23
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
- FDA-regulated device study
Source: ClinicalTrials.gov record NCT03805984. Inclusion in this directory is not an endorsement.